Related Experiment Video
Updated: Nov 17, 2025

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
Predictors of survival in paediatric mitral valve replacement
Gianluca Brancaccio1, Matteo Trezzi1, Marcello Chinali2
1Department of Pediatric Cardiac Surgery, Bambino Gesù Children's Hospital, Rome, Italy.
Insights
Mitral valve replacement (MVR) in children is effective, with mortality predicted by prosthesis size/weight ratio and age under 2 years. Re-replacement is feasible, allowing for larger valve implantation.
Area of Science:
- Pediatric Cardiology
- Cardiovascular Surgery
- Biomedical Engineering
Background:
- Congenital or acquired mitral valve disease in children often necessitates surgical intervention.
- Mitral valve replacement (MVR) is a critical procedure for managing unrepairable mitral valve disease in pediatric patients.
- Predicting outcomes and identifying risk factors for MVR in children is essential for optimizing patient care.
Purpose of the Study:
- To identify predictors of mortality and reintervention following MVR in pediatric patients.
- To assess the long-term efficacy and safety of MVR in children.
- To evaluate the feasibility of mitral valve re-replacement in pediatric cases.
Main Methods:
- A retrospective single-center study included 115 pediatric patients (<18 years) who underwent MVR between 1982 and 2019.
- Calculated the ratio of prosthetic valve size to patient weight (mm/kg) at surgery.
- Assessed long-term outcomes including freedom from re-replacement and death/transplant-free survival.
Main Results:
- Death/transplant-free survival was 77±4% at 5 years and 72±5% at 10 years.
- A size/weight ratio >2 and age <2 years were significant risk factors for death or transplant.
- Biological prosthesis and a size/weight ratio >2 predicted reoperation; significant prosthesis upsizing was noted at re-replacement.
Conclusions:
- Mitral valve replacement is a viable strategy for children with severe mitral valve disease.
- Prosthesis size/weight ratio and early childhood age (<2 years) are key predictors of mortality after MVR.
- Mitral valve re-replacement in children can be performed with acceptable morbidity and mortality, often accommodating larger prostheses.
Objectives:
The aim of this study was to identify the predictors of death and of reintervention after mitral valve replacement (MVR) in children.
Methods:
A single-centre retrospective study was performed including 115 patients under the age of 18 undergoing MVR between 1982 and 2019. For all patients, the ratio of prosthetic valve size (diameter in mm) to weight (kg) at surgery was calculated and long-term result was assessed. The primary outcome was freedom from mitral valve (MV) re-replacement. The composite secondary outcome was freedom from death or transplant.
Results:
Fifty-four patients had a previous surgical attempt to MV repair. The median age at surgery was 5.5 years (interquartile range 1.21-9.87). Death/transplant-free survival was 77 ± 4% at 5 years and 72 ± 5% at 10 years. Univariate analysis showed a size/weight ratio higher than 2 and age <2 years as significant risk factors for death or transplant. Freedom from MV re-replacement at 5 and 10 years was 90 ± 3% and 72 ± 6%, respectively. Biological prosthesis implanted at first replacement (P = 0.007) and size/weight ratio higher than 2 (P = 0.048) were predictors of reoperation. Significant upsizing (P < 0.0001) of mitral prosthesis was observed at re-replacement.
Conclusions:
MVR is a viable strategy in children with unrepairable MV disease. Mortality can be predicted based on size/weight ratio and age <2 years. MV re-replacement can be performed with low morbidity and mortality and a larger-size prosthesis can often be placed at the time of redo.
Related Concept Videos
Mitral Valve Prolapse II: Assessment and Management
Mitral Valve Prolapse I: Introduction
Mitral Stenosis III: Medical Management
Mitral Valve Prolapse III: Nursing Management
Mitral Regurgitation IV: Nursing Management
Mitral Stenosis IV: Nursing Management

